{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "OSCR",
  "name": "Oscar Health, Inc.",
  "url": "https://orbyd.app/dossiers/OSCR/",
  "json_url": "https://orbyd.app/dossiers/OSCR.json",
  "status": "HELD",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "The August 6 binary resolved on the numbers and broke on the tape: EPS $1.10 vs $0.49, guidance raised $250M, stock closed $26.54 from $30.11 and $27.90 on August 7. What is left to buy is a post-print reset into the September 16 Investor Day and the ~September 30 subsidy vehicle, against a full-year guide that sits below the half-year result. Theme reads SATURATED.",
  "invalidation_trigger": "A weekly close below $26.50 confirms the August 6 gap-down as distribution — it loses the $26.54 post-print reaction close and the $26.50 median target. Secondary: the ~September 30 appropriations vehicle passing with no enhanced premium tax credit extension attached.",
  "catalyst_date": "2026-08-14",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Single-segment ACA individual-market insurer: no Medicaid or Medicare Advantage book to offset a marketplace quarter, unlike CNC, MOH or ELV.",
    "Management guides MLR lowest in Q1 and highest in Q4, so quarterly loss ratios are not comparable sequentially; judge each against the 81.5-82.5% FY range.",
    "Premium is overwhelmingly federally subsidized exchange business, so Congressional premium-tax-credit headlines move the stock independent of operating results.",
    "Dual-class structure: Class B converts 1:1 into Class A, so insider conversions add Class A float without changing economic ownership of the company.",
    "Five-year beta has run above 2 on a float of roughly 249M shares against 308.32M shares outstanding, so index-level moves are amplified."
  ],
  "body_markdown": "## Current Thesis\n\nThe binary the prior note was waiting on has been graded. Oscar reported Q2 before the open on August 6 2026: EPS $1.10 against a $0.49 consensus, revenue $4,880.2M against $4,751M expected, earnings from operations $388.6M versus a $230.5M operating loss in Q2 2025, and full-year earnings-from-operations guidance raised by $250M to $500–700M. The stock closed $26.54 that session against $30.11 on August 5, then recovered to $27.90 on August 7 (+5.12%). The $28 weekly line the prior note named as the thesis-break level gave way on that Friday close.\n\nWhat the market repriced was not the quarter but the shape of the rest of the year. First-half earnings from operations of $1,092.7M sit above the entire raised full-year band; CFO Scott Blackley told the call that membership churn previously framed at 1–2% is now expected at roughly twice that in the back half, tied to CMS program-integrity eligibility and data-matching processes that slipped out of Q2. Effectuated membership was 2,963,002 at June 30, against 3.17M reported at March 31.\n\nThe leg an investor would now be buying is a post-print reset — proven underwriting margin, a raised guide, four sell-side target increases in two sessions — held against a second half management has told the market will be worse and a subsidy decision that is not on the calendar. Theme reads SATURATED, dated August 6 2026: a beat of more than twice consensus EPS plus a $250M guidance raise produced a double-digit down session, and the target raises arrived after the repricing rather than ahead of it.\n\n## Bull Case\n\n- **The margin recovery is now reported for two consecutive quarters, not modelled.** Q2 2026 MLR 79.2% against 91.1% in Q2 2025; H1 MLR 75.0%; H1 net income $1,040.8M on revenue $9,527.4M (results release, 2026-08-06).\n- **Guidance moved up on three of four lines.** Full-year MLR cut to 81.5–82.5% from 82.4–83.4% (90bp better at the midpoint), SG&A ratio to 15.6–16.1% from 15.8–16.3%, earnings from operations to $500–700M from $250–450M, revenue reaffirmed at $18.7–19.0B.\n- **Cost control ran ahead of the guide.** Q2 SG&A expense ratio 14.2%, H1 14.7%, against a full-year band of 15.6–16.1%.\n- **The sell-side board moved up hard after the print.** Barclays $35 → $39 (Andrew Mok, Overweight, 2026-08-07), Baird $19 → $27, UBS $20 → $26 (Neutral), Bank of America $13 → $25. Mean target $28.20 from $25.20 on August 4; the low target rose to $19 from $13.\n- **Membership growth is still the largest in the group.** 2,963,002 effectuated members at June 30, +46% year over year, while Molina reported 283,000 marketplace members against 655,000 at end-2025 (Molina Q2, 2026-07-22).\n- **2027 pricing is being filed up across the industry.** KFF's July 8 2026 review of preliminary filings found a median 14% proposed increase across 77 carriers in 16 states and DC, 20 of them above 20%.\n- **A second dated re-rating event is already scheduled.** Investor Day September 16 2026, 9:00 AM ET, where long-term targets and the first 2027 framework get set (announced 2026-07-28).\n\n## Bear Case\n\n- **The raised full-year band is below the half-year result.** Earnings from operations $1,092.7M for H1 against a $500–700M full-year guide; consensus full-year EPS stands at $1.55 while Q1 diluted EPS was $2.07 and Q2 $1.10.\n- **Quality of the beat.** Q2 included $164M of favorable prior-period reserve development — earnings sourced from prior-year claims experience rather than current-period underwriting.\n- **Churn guidance doubled inside one call.** Blackley put back-half membership lapse at roughly twice the previously communicated 1–2%, attributed to CMS eligibility and data-matching processes; management framed it as timing and left revenue guidance unchanged, which puts the burden of proof on the Q3 membership count.\n- **Price is now below the average target it spent July above.** August 7 close $27.90 against a $28.20 mean and a $26.50 median, with the board still 3 Buy / 7 Hold / 1 Sell across 11 analysts.\n- **The subsidy option remains unpriced and unscheduled.** Enhanced premium tax credits lapsed December 31 2025; the House-passed three-year extension (230–196, January 8 2026) has not cleared the Senate, where S. 3385 failed to reach 60 votes.\n- **Insider supply preceded the break.** CEO Mark Bertolini sold 1,238,996 Class A shares June 29–30 2026 at weighted averages of $27.78–$30.61 under a 10b5-1 letter dated November 10 2025 (amended March 24 2026), cutting his direct holding to 7,751,570 from 8,990,566 (Form 4 filed 2026-07-01).\n- **The sector has been punishing good prints.** Elevance beat Q2 on July 15 2026 and its conservative guidance raise sold managed care off broadly; Oscar's own August 6 session repeated the pattern.\n\n## Setup & Price Structure\n\nThe post-print sequence is the structure: $30.11 close August 5, $26.54 close August 6, $27.90 close August 7 on a 5.12% bounce. That August 7 weekly close sits under every July close (the lowest was $28.19 on July 24), under the 50-day moving average measured at $28.26 on August 4, and 30 cents under the current $28.20 mean target. The 52-week range is $10.69 to $33.10; the run's ceiling remains the $33.10 high and the $31.94 intraday print of July 29.\n\nCrowding and positioning observables, stated as observables:\n\n- Four price-target raises landed inside two sessions on August 7–8 (Barclays, UBS, Baird, Bank of America) — after the August 6 gap-down, not before it. The rating mix did not change: 3 Buy / 7 Hold / 1 Sell.\n- Short interest stood at 19.58M shares, 7.86% of a 249.19M float, 3.33 days to cover at the most recent FINRA settlement, up from 17.47M a month earlier. The next report covering the mid-August settlement date is the first post-print positioning update.\n- Participation had already been contracting into the print: four consecutive below-average volume sessions through August 4, against a twenty-day average that itself decayed from 4.15M to 4.01M shares.\n- Insider direction was one-way in the last week of June (see Form 4 above); a co-founder trust converted Class B to Class A and sold on July 1 2026.\n- Consensus forward estimates now sit at $18.57B revenue and $1.55 EPS for FY2026, and $20.00B and $1.70 for FY2027 — a 7.72% revenue growth step-down from 2026's 58.69%.\n\nThe base has not re-formed. One up-session off a gap-down close is a single observation, and the August 6 low close of $26.54 is the reference the tape has not yet retested.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-14** — Q2 2026 13F filing deadline. First institutional read on whether the holder base broadened through the June–July re-rate or thinned into the August 6 break.\n- **~2026-08-26 (est.)** — FINRA short-interest report for the mid-August settlement date. Shows whether the 19.58M-share base grew into the gap-down or covered on it.\n- **~2026-08-31 (est.)** — State regulators continue finalizing 2027 ACA rates against the 14% median proposed in the July filings. The gap between filed and approved sets 2027 revenue per member.\n- Beyond the 30-day window but dated: **2026-09-16** Investor Day, 9:00 AM ET (long-term targets, first 2027 framework); **~2026-09-30** federal appropriations deadline, the next plausible vehicle for an enhanced-premium-tax-credit extension; **~2026-11-01 (est.)** 2027 open enrollment opens; **~2026-11-05 (est.)** Q3 2026 print, the first hard check on back-half churn and the $500–700M band.\n\n## What Would Change Our Mind\n\nThe August 6 gap-down is the structure that now governs. Treating it as a reset requires the $26.54 reaction close to hold on any retest; a weekly close below $26.50 loses that close and the $26.50 median analyst target together, and would read the session as distribution rather than repricing. Secondary conditions that would break the leg independent of price: the ~September 30 appropriations vehicle passing with no enhanced premium tax credit extension attached and no reconciliation vehicle named, which retires the subsidy option entirely; or a Q3 membership count that lands materially below 2,963,002 with revenue guidance cut, which would recast the \"timing\" framing of the churn as a permanent base reduction.\n\nWhat would rebuild the case: a September 16 Investor Day that guides 2027 marketplace membership and premium up rather than down, against Molina having stripped roughly $1B of marketplace premium out of its own 2027 plan (2026-07-22); or a Q3 MLR inside the new 81.5–82.5% band without reliance on prior-period development.\n\n## Correlation Notes\n\n- Oscar trades as the highest-beta expression of ACA marketplace policy. It carries no Medicaid or Medicare Advantage book, so peer results only rationally transfer through the exchange segment: Centene's 79.2% Q2 health benefits ratio and its FY2026 adjusted-EPS raise to more than $4.80 from more than $3.40 (2026-07-28) was a positive exchange read; Molina's cut to a $0.75/share full-year marketplace loss (2026-07-22) was the opposite.\n- Group-level risk appetite dominates on some days regardless of company news — the July 15 2026 Elevance print sold the whole managed-care complex down on a beat.\n- Policy headlines (premium tax credits, CMS program-integrity rules) move the stock independent of operating results, and those headlines are unscheduled between now and the ~September 30 appropriations deadline.\n- The name's five-year beta has run above 2, so index-level drawdowns are amplified into a float of roughly 249M shares against 308.32M shares outstanding.",
  "first_seen": "2026-04-29",
  "last_analyzed": "2026-08-09T09:32:31+00:00",
  "last_synthesized": "2026-08-09",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}